Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q1 2026 · 10-Q
Revenue$141.00K$141.00K+95.8% vs Q1 2025 Net Income-$104.90M-$104.90MN/M vs Q1 2025 EPS, diluted—
Operating Income-$116,169,000N/M Operating Cash Flow-$119,654,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
Free Cash Flowderived-$119,677,000N/M Margins · derivedOperating margin-82389.4%+47980.1 pt vs Q1 2025
Net margin-74397.9%+46313.2 pt vs Q1 2025
ended Mar 31, 2026 · filed May 5, 2026 · 35 d after period end